Related Experiment Video
Updated: Nov 2, 2025
Integration of Bioinformatics Approaches and Experimental Validations to Understand the Role of Notch Signaling in Ovarian Cancer
Published on: January 12, 2020
Assessment of Significant Pathway Signaling and Prognostic Value of GNG11 in Ovarian Serous Cystadenocarcinoma
Ming-Min Jiang1, Fan Zhao1, Tao-Tao Lou1
1Department of Obstetrics and Gynaecology, Zhuji Central Hospital, Shaoxing, 311800, Zhejiang, People's Republic of China.
Background:
GNG11 (G protein subunit gamma 11) is a member of guanine nucleotide-binding protein (G protein) gamma family. Few studies elucidated the role of GNG11 in human disease, especially in tumors. The present study initially analyzed the function of GNG11 in ovarian serous cystadenocarcinoma.
Methods:
The differential expression of GNG11 mRNA in ovarian cancer and normal tissues was evaluated through Oncomine, CCLE, Gepia, UCSC Xena and UALCAN databases. The protein expression of GNG11 was assessed via HPA database. Prognosis analysis was performed by Kaplan-Meier Plotter. Restrict survival analysis to subtypes including tumor grade, cancer stage and TP53 mutation status was then carried out. GSEA enrichment analysis was performed to explore the significant pathways associated with GNG11 in ovarian cancer. Finally, the upstream miRNAs of GNG11 were predicted by DIANA, Target Scan, miRDB and miRWalk databases, and the potential key KEGG pathways were subsequently determined by DIANA.
Results:
The mRNA expression of GNG11 was down-regulated in ovarian cancer patients (P<0.05). The cancer stage of patients correlated with the expression of GNG11 (P<0.05). Survival analysis indicated that GNG11 high expression statistically shortened the overall survival time of patients (HR=1.26, P=0.0043) compared with low expression group, especially for the patients with earlier stage (HR=2.48, P=0.035) and lower grade (HR=1.72, P=0.0016). Subsequently, the consistent upstream miRNA of GNG11, hsa-miR-22-5p, was predicted from 4 databases. The differential expression profile of hsa-miR-22-5p in blood was observed in ovarian cancer patients. According to the GSEA analysis on GNG11 and KEGG analysis on hsa-miR-22-5p, the consistent pathway of ECM-receptor interaction was observed (all P<0.01). ECM-receptor interaction pathway and differential expression of hsa-miR-22-5p in blood suggested the migration risk of ovarian cancer.
Conclusion:
High expression of GNG11 indicated the poor prognosis of ovarian cancer patients. GNG11 might play a crucial role in the biological process of ovarian serous cystadenocarcinoma by ECM-receptor interaction pathway, thus affecting the prognosis of patients.
Insights
High GNG11 expression indicates poor prognosis in ovarian cancer patients. This suggests GNG11 plays a role in ovarian serous cystadenocarcinoma progression via the ECM-receptor interaction pathway.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- GNG11 (G protein subunit gamma 11) is a guanine nucleotide-binding protein gamma family member.
- Limited research exists on GNG11's role in human diseases, particularly in cancer.
Purpose of the Study:
- To investigate the function of GNG11 in ovarian serous cystadenocarcinoma.
- To analyze the prognostic value of GNG11 in ovarian cancer.
Main Methods:
- Utilized bioinformatics databases (Oncomine, GEPIA, etc.) to assess GNG11 mRNA and protein expression.
- Performed survival analysis using Kaplan-Meier Plotter and GSEA.
- Predicted upstream miRNAs and associated KEGG pathways.
Main Results:
- GNG11 mRNA expression was downregulated in ovarian cancer tissues.
- High GNG11 expression correlated with shorter overall survival, particularly in earlier stages and lower grades.
- Identified hsa-miR-22-5p as a consistent upstream miRNA, linked to the ECM-receptor interaction pathway.
Conclusions:
- Elevated GNG11 expression is associated with poor prognosis in ovarian cancer.
- GNG11 may influence ovarian serous cystadenocarcinoma progression through the ECM-receptor interaction pathway.
